



EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. in Million, except per equity share data)

free trimmon, except be equity and e used			ary on a o among
Particulars	3 months ended 31.12.2019 (Unaudited)	9 Months ended 31.12.2019 (Unaudited)	3 months ended 31.12.2018 (Unaudited)
Net profit before share of profit of joint venture and associates, tax, exceptional items and non-controlling interest	3,183	9,349	2,710
Net profit before tax and non-controlling interest	3,151	9,819	2,893
Net profit after tax and non-controlling interest	2,028	6,248	2,172
Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	2,096	5,405	2,213
Paid-up equity share capital [Face value of Rs. 5 each]	6,000	6,000	3,000
Earnings per share [of Rs. 5 each] (a) Basic (b) Diluted	(not annualised) 1.71 1.71	(not annualised) 5.28 5.27	(not annualised) 1.84 1.82
	Total income from operations Net profit before share of profit of joint venture and associates, tax, exceptional items and non-controlling interest. Net profit before tax and non-controlling interest. Net profit after tax and non-controlling interest. Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)] Paid-up equity share capital [Face value of Rs. 5 each] Earnings per share [of Rs. 5 each] (a) Basic	Particulars Comparison of the period attributable to shareholders [comprehensive income (after tax)] Paid-up equity share capital [Face value of Rs. 5 each] 3 months ended 31.12.2019 (Unaudited) 17,481	Particulars Comparison of the period attributable to shareholders [comprehensive income (after tax)]

1. Key standalone financial information

(Rs. in Million)

	Particulars	3 months ended 31.12.2019	9 Months ended 31.12.2019 (Unaudited)	3 months ended 31.12.2018 (Unaudited)
		(Unaudited)		
- 2	Continuing operations	177 335		1000
1	Total income from operations	5,013	15,060	4,434
11	Profit before tax	1,578	4,397	509
Ш	Profit after tax	1,207	3,427	443
112000	Discontinuing/discontinued operations	(0.00000)	120000	
1	Profit before tax		117	311
II	Profit after tax	100	(40)	284

- The unaudited standalone and consolidated financial results for the quarter and nine months ended. December 31, 2019 in respect of Biocon Limited (the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 23, 2020. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133
 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and
 Disclosure Requirements) Regulations, 2015.
- 4. The above is an extract of the detailed format of unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.

කිස්ಯವಾಣೆ 🞫







EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. in Million, except per equity share data)

_		(113. III Million, except per equity share data)			
	Particulars	3 months ended 31.12.2019 (Unaudited)	9 Months ended 31.12.2019 (Unaudited)	3 months ended 31.12.2018 (Unaudited)	
1	Total income from operations	17,481	47,862	15,408	
11	Net profit before share of profit of joint venture and associates, tax, exceptional items and non-controlling interest	3,183	9,349	2,710	
111	Net profit before tax and non-controlling interest	3,151	9,819	2,893	
IV	Net profit after tax and non-controlling interest	2,028	6,248	2,172	
٧	Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	2,096	5,405	2,213	
VI	Paid-up equity share capital [Face value of Rs. 5 each]	6,000	6,000	3,000	
VII	Earnings per share [of Rs. 5 each] (a) Basic (b) Diluted	(not annualised) 1.71 1.71	(not annualised) 5.28 5.27	(not annualised) 1.84 1.82	

1.Key standalone financial information

(Rs. in Million)

	Particulars	3 months ended 31.12.2019	9 Months ended 31.12.2019 (Unaudited)	3 months ended 31.12.2018 (Unaudited)
		(Unaudited)		
	Continuing operations			
T	Total income from operations	5,013	15,060	4,434
11	Profit before tax	1,578	4,397	509
Ш	Profit after tax	1,207	3,427	443
	Discontinuing/discontinued operations			
1	Profit before tax		117	311
11	Profit after tax	ă ă	(40)	284

- 2. The unaudited standalone and consolidated financial results for the quarter and nine months ended. December 31, 2019 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 23, 2020. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- 3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 4. The above is an extract of the detailed format of unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.